Montelukast Sodium Oral Granules
Belongs to Category:
The company has production licenses for tablets, capsules, granules, suppositories, powders, injections, oral solutions, dry suspensions, and eye drops.
Product Description
Approval Number:
H20233975
Indications:
This product is indicated for the prevention and long-term treatment of asthma in children aged 1 year and older, including the prevention of daytime and nighttime asthma symptoms, the treatment of asthma patients sensitive to aspirin, and the prevention of exercise-induced bronchoconstriction.
This product is also indicated for the relief of symptoms caused by allergic rhinitis (seasonal and perennial allergic rhinitis in children aged 2 to 5 years).
Administration:
Once daily. Asthma patients should take it at bedtime. Patients with allergic rhinitis may take it at a time that suits their needs.
Patients with both asthma and allergic rhinitis should take the medication once every evening.
Children aged 1 to 2 years with asthma: One sachet daily.
Children aged 2 to 5 years with asthma and/or allergic rhinitis: One 4 mg oral granule sachet daily.
Administration of Oral Granules
This product can be taken directly, mixed with a spoonful of room-temperature or cold soft food (e.g., applesauce), or dissolved in a teaspoon of room-temperature or cold infant formula or breast milk. The sachet should be opened only at the time of administration. Once opened, the entire dose should be taken immediately (within 15 minutes). The mixture of the product with food, infant formula, or breast milk should not be stored for later use. This product should not be dissolved in any liquid other than infant formula or breast milk. However, water may be consumed after administration.
General Recommendations
The therapeutic effect should be evaluated based on asthma control indicators. The efficacy of this product may be observed within one day of administration. It can be taken with or without food. Patients are advised to continue taking the medication, regardless of whether their asthma is under control or worsening.
Dosage adjustments may be necessary for patients with respiratory insufficiency, mild to severe skin conditions, or other specific conditions.
Relationship with Other Asthma Medications
This product can be added to a patient’s existing treatment regimen.
Reduction of Concomitant Medications:
Bronchodilators
For asthma patients not adequately controlled with bronchodilators alone, this product may be added to the treatment regimen. Once a clinical response is observed (usually after the first dose), the bronchodilator dosage may be reduced based on the patient’s tolerance.
Inhaled Corticosteroids
For asthma patients receiving inhaled corticosteroids, the corticosteroid dosage may be reduced based on the patient’s tolerance after adding this product. The reduction should be gradual and under medical supervision. Some patients may gradually reduce the dosage until inhaled corticosteroids are completely discontinued. However, this product should not be used as a sudden replacement for inhaled corticosteroids or oral corticosteroids.
Specifications:
4mg × 7 bags
The company has production licenses for tablets, capsules, granules, suppositories, powders, injections, oral solutions, dry suspensions, and eye drops.
The main products cover cardiovascular diseases, diabetic complications, anti-tumor, calcium supplementation, digestive system, respiratory system, and orthopedics.
Related Products
Online Message
We will contact you within one business day. Please pay attention to your email.
Email: marcos.yuan@wangao.com.cn
Address: No. 688, Dinghai Road, Haimen City, Jiangsu Province
Mobile Version QR Code
WeChat Official Account
Copyright © 2025 Jiangsu Wangao Pharmaceutical Co., Ltd.